Hyperbaric Oxygen Therapy for Autism: No Quality Evidence Supports Its Use

Evidence Review: HBOT and Autism Spectrum Disorder

Despite anecdotal claims and off-label clinic offerings, there is no high-quality scientific evidence that hyperbaric oxygen therapy (HBOT) improves core symptoms of autism or associated behavioral disorders.

Current Evidence Base

• Systematic Reviews (Cochrane, 2016; others): Found only small, methodologically flawed studies with high risk of bias. No randomized controlled trials (RCTs) demonstrated clinically meaningful benefit.
• Major Professional Societies: AAP, AACAP, and international autism research consortia do not recommend HBOT for ASD.
• FDA Warning: The FDA has not cleared HBOT for autism and has issued consumer warnings against unproven claims.

Risks of HBOT

• Barotrauma (ear, sinus, lung).
• Oxygen toxicity (seizures).
• Fire hazard in oxygen-enriched chambers.
• Financial cost ($100–$300/session; typically 40+ sessions promoted).
• Opportunity cost: diverts time/resources from evidence-based interventions (ABA, speech/OT, educational supports).

Conclusion

HBOT should not be used as a treatment for autism outside of rigorous clinical trials. Families should prioritize therapies with robust evidence and consult qualified developmental pediatricians or child psychiatrists for individualized care plans.